Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Adipose-derived mesenchymal stem cells improved acute renal failure induced by ischemia-reperfusion injury: Focusing on toll-like receptor 4 activity and endoplasmic reticulum stress response.

Hafazeh L., Kadkhodaee M., Seifi B., Akhondzadeh F., Azedi F., Noori H.

Animal Study on Chronic Kidney Disease, Acute Kidney Injury, published in J Physiol Biochem (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Physiol Biochem (2026)
Country
Spain
Reported sample size
—
Source database
PubMed
PMID
42435285
DOI
10.1007/s13105-026-01207-w

Abstract (original English)

This study evaluated the efficacy of adipose-derived mesenchymal stem cells (AD-MSCs) in reducing pathological alterations linked to acute kidney injury (AKI) caused by ischemia-reperfusion injury (IRI). In this study, 18 male rats were divided into three groups: Sham, IRI, and IRI + AD-MSC. IRI was induced by clamping the renal pedicles for 45 min, while the Sham group animals underwent the same surgical procedure without vascular clamping. In the IRI + AD-MSC groups, immediately after clamp removal, the animals received an intraperitoneal injection of 1 × 10⁶ AD-MSCs. To enable tracking, AD-MSCs were transfected with green fluorescent protein (GFP). The distribution of these labeled cells was examined at 24 and 48 h post-transplantation in three additional rats. Forty-eight hours after reperfusion, serum and kidney tissue samples were collected. The labeled AD-MSCs were more widely distributed in the injured kidney area of the IRI + AD-MSC group compared to the control group. In the group treated with AD-MSCs, there were notable reductions in serum blood urea nitrogen (BUN) and creatinine levels (P < 0.001), along with improvements in renal tissue damage and oxidative stress (P < 0.01). Additionally, the IRI + AD-MSC group showed significant decreases in toll-like receptor-4 (TLR4) protein levels (P < 0.01) and pro-inflammatory factors (P < 0.001), as well as reduced levels o

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsToll-Like Receptor 4Reperfusion InjuryMaleAcute Kidney InjuryMesenchymal Stem Cell TransplantationEndoplasmic Reticulum StressMesenchymal Stem CellsRatsAdipose Tissue

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research